Company news
TransThera Sciences (Nanjing). Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Next Day Disclosure Return
November 2, 2026
Inside information announcement grant of listing approval by the stock exchange for implementation of the h share full circulation
November 1, 2026
Next Day Disclosure Return
October 27, 2026
Inside information announcement issuance of the filing notice by the csrc for the h share full circulation by the company
October 26, 2026
Next Day Disclosure Return
October 26, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 22, 2026
Voluntary announcement business update on commercialisation of core product yochanra
October 21, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
Interim report 2026
September 21, 2026
Voluntary announcement first patient dosed in phase II clinical trial of tinengotinib in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer in China
September 18, 2026
Voluntary announcement inclusion of yochanra (tinengotinib) in the CSCO guidelines for the diagnosis and treatment of biliary tract cancers (2026)
September 18, 2026
New drug application for Tinengotinib tablets accepted by the national medical products administration
December 18, 2025
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
December 4, 2025
Inclusion of Tinengotinib tablets in the list of products for priority review by the national medical products administration
December 3, 2025